2 results
Approved WMOCompleted
PHASE IIPrimary ObjectiveThe primary objective of the Phase II portion of the study is to estimate the efficacy as measured by radiographic progression-free survival of IPATASERTIB (GDC-0068) (dosed at either 400 mg or 200 mg daily) + abiraterone…
Approved WMORecruiting
The primary objective is to test the feasibility (Study 1) and the effectiveness (Study 2) of using self-tracking device and web-based coaching platform to increase PA levels among patients in the early CR process. Effectiveness of the new approach…